TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report issued on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price target on the stock.

A number of other research analysts have also recently commented on the company. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.56.

TriSalus Life Sciences Price Performance

TLSI stock opened at $5.53 on Thursday. The stock has a market cap of $168.63 million, a price-to-earnings ratio of -2.22 and a beta of 0.51. The company has a 50 day simple moving average of $4.79 and a 200 day simple moving average of $4.74. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.42.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 5,030 shares of the stock in a transaction dated Wednesday, January 29th. The stock was purchased at an average cost of $5.03 per share, with a total value of $25,300.90. Following the transaction, the chief executive officer now owns 439,249 shares in the company, valued at approximately $2,209,422.47. The trade was a 1.16 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Equity Ab Frankenius acquired 62,972 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 124,868 shares of company stock worth $575,843 over the last ninety days. Insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the period. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at $184,000. Walleye Capital LLC bought a new position in TriSalus Life Sciences during the third quarter worth $66,000. Renaissance Technologies LLC acquired a new stake in TriSalus Life Sciences in the fourth quarter worth $67,000. Finally, Virtu Financial LLC bought a new stake in TriSalus Life Sciences in the third quarter valued at $92,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.